Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
or at the market.
like everyone else I would like to know why EMH is not optioning D2. many seem to think there is some large deal coming, which of course would be great! but maybe EMH is just feeling between a rock and a hard place. maybe if they spend on D2 they won't have the money to respond to a PSF buyout offer from VFF. any thoughts? is that too far out?
Vector93, pretty sure you are right, it has had a very good run. not surprising to see a pullback. some people are sure to take some profit.
speaking of licenses I wonder what has happened to pntvs. did they sell them and pocket the money? since they don't seem to have any going concern in nevada or california what do they need them for?
I think things look bright for EMH in the future and I am taking a chance waiting for the 4th quarter report. I just have a hunch it will not be as great as everyone seems to think. I am expecting great things just not before the 1st or 2nd quarter of this year.
I have a little money to buy some more but I'm waiting till after the 4th quarter report, so for me it's "the sooner the better"
Emerald Bioscience ( was Nemus Bioscience) was sure on a tear today. wonder what is up.
I think it moved to the end of April! :^(
WOW, almost a 30% day, looks like it finished at .8150 I'll take it! :^)
So EMBI is now Emerald Bioscience inc. The new name and symbol of what was NEMUS Bioscience. It has been on a tear lately, sure hope it continues
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
03/25/2019
Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group
Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019
LONG BEACH, CA , March 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that it has changed its corporate name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc. The company’s new OTCQB ticker symbol, “EMBI,” will be effective at the market open on March 25, 2019 . The new website for Emerald Bioscience is www.emeraldbio.life .
“Our new name better represents our relationship with the Emerald Group and our common goal to be leaders in advancing cannabinoid science. We have made strong progress in the past year. With our robust pipeline based on our proprietary bioengineered cannabinoid technology, partnerships with leading institutions, and strides in manufacturing, we are committed to developing therapies that will change the lives of patients with significant unmet medical needs,” said Brian Murphy , MD, CEO and Chief Medical Officer of Emerald Bioscience, Inc.
Recent Scientific Advancements
Preclinical data demonstrated NB1111, Emerald Bioscience’s proprietary prodrug of THC (THC-VAL-HS), is statistically superior in lowering intraocular pressure (IOP) compared to the current standard-of-care, latanoprost, for the treatment of glaucoma across multiple timepoints during a seven-day course of repeated dosing using a validated rabbit normotensive ocular model.
Data generated by Glauconix Biosciences, Inc. further validated the mechanism of action of NB1111 in lowering intraocular pressure (IOP), a defining symptom of hypertensive glaucoma. In this study, NB1111 improved fluid outflow across the trabecular meshwork and positively impacted disease markers associated with glaucoma-related fibrosis and inflammation.
Strategic Advancements
Signed an agreement with Pharmaceuticals International Inc. , a contract development manufacturing organization, to develop a sterile eyedrop dosage formulation of NB1111 for human dosing.
Signed an agreement with Noramco, Inc. for the manufacturing and scale-up of Emerald Bioscience’s proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi .
As the company prepares to advance its lead product candidate, NB1111, into a Phase 1b/2a clinical trial for the treatment of glaucoma, this name change allows the company the opportunity to develop a strong and unique global brand that reflects its recent advancements in the rapidly-evolving field of cannabinoid science.
Emerald Bioscience is part of the Emerald Group , which is comprised of a strong network of companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Existing shareholders interested in getting an updated statement representing book shares or a revised stock certificate, please email our transfer agent, ClearTrust, LLC , at inbox@cleartrusttransfer.com .
About Emerald Bioscience, Inc.
Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California , focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi , Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.
Emerald Bioscience is part of the Emerald Group , which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.
For more information, visit www.emeraldbio.life
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and
commercialization
Isn't EMH scheduled to report on the day after on the 14th?
dang, still under a buck us
can't stand it any longer so I'm out with a small profit. If it drops after earning maybe I can get back in at a better average.
Oh I'm pretty sure THEY have made money!
not sure why this NR is so great, isn't this just an announcement of the name change? didn't we know all but the name before?
who forecast $50.00 this year?
BobFL, might as well give up! :^)
It is totally amazing that this thing has held up so well for so long! It should have dropped sub penny months and months ago.
Probably not much as they have no revenue and even it they did owe taxes we all know that The Boys never complete anything so I'm sure it would still be owing! LOL :^)
Just bought a few more at $1.70 so I wouldn't be surprised either! :^)
Well this sucks, my shares that I saw in my schwab account seem to have been pulled back. called schwab and they couldn't say why but that I should receive my shares before too long.
P.S. Does anyone know why they are calling this board Adventure gold inc
yep,they showed up in my account yesterday.
the ticker on the OTC does need changing.
Wow still halted!? Not sure I remember a halt this long without news. does not bode well for Ascent. sure hope I am wrong!
Wow, up 25% on heavy volume, I was sure this would be down alot this morning! nice surprise! :^)
WOW! eight times volume and no news, I hope this is a loose lips thing and not some rich guy or company taking a position all at once.
greenbacks,any one looking into CTSO and not seeing a big winner is not looking very close. Even big winners go down sometimes, nothing goes straight up. If you have not locked in those losses of 30 percent hold tight and you will end up a big winner! good luck to you.
Here is to a great tomorrow for emerald. But I kind of think tomorrow will be kind of a non-event as far as share price goes!
Was gone most of the day, came back to find a nice 54% gain! SWEET!! :^)
Such a busy board,can't hardly keep up with my reading!
Nice high of the day finish! :^)
nice e-mail from Ascent:
Ascent_Industries_Corp
Ascent_Industries
Hello,
As we inch closer to adult-use cannabis legalization in Canada, the team and I want to thank you for your continued support. Being at the forefront of this global shift in the conversation around cannabis has been an honour and a privilege, and, with your help, we will continue to establish ourselves as an international leader in cannabis.
In late September, it was brought to our attention that Agrima Botanicals did not meet all of its record keeping and other compliance requirements during a recent inspection. As a result, Health Canada has partially suspended Agrima Botanicals’ licenses. Ascent has taken steps to correct this non-compliance issue and anticipates having the licenses reinstated in the near future. We will continue to keep investors informed throughout the process.
Licensing issue aside, September was a great month for Ascent. We are pleased to announce that Ascent is now included in the CSE 25 Index. Earlier in September, our wholly owned subsidiary, Agrima Botanicals, signed supply agreements with the provinces of Ontario and British Columbia. Meanwhile, Agrima’s science division has developed a new methodology for producing water-soluble cannabinoids, enabling new and exciting avenues for product infusion in the beverage and edibles space. And on a final note, we are pleased with the continued development of AIC Health and are excited to get our cannabis-focused medical clinics operational within the coming months.
Remember, October 17th is a milestone, not an end goal. With legalization on the horizon, we expect bigger and better things in the near future and are grateful for you to be joining us on this journey.
Thanks again for all your support,
Philip_Campbell
PHILIP CAMPBELL
CO-FOUNDER, DIRECTOR & CEO
Copy of sweet_cannabis_wide_PNG_4000-1
Product Updates
Last month, Sweet Cannabis PDX launched a new line of Grace Notes Edibles. Available in both THC and CBD formulations, Grace Notes Chocolate Bars combine quality ingredients with top-tier cannabis and are available in three unique flavours. The Grace Notes line is rounded out with single serve Bites and Taffy Notes, both of which are also available through Sweet Cannabis Nevada.
Grace_Notes_Taffy
On the medicinal front, the Nu product line continues to perform well, with the CBD tinctures and gel caps being particularly strong sellers.
Nu_Tinctures
Looking ahead, we will be rolling out some big improvements to Toko , our line of sleek and discreet cannabis vape products. The high-quality cannabis oil Toko is known for isn’t changing - we are simply updating our cartridges. In the coming months, we will be replacing our current steel and wick cartridge format with ceramic cell coils. We are always listening to feedback from our clientele, and are making this change to ensure that we continue to give consumers the best possible cannabis vaping experience.
Company News
The company accomplished several key objectives this month, including the recent formation of AIC Health and our addition to the CSE25 Index. With these developments, we are well positioned moving forward and one step closer towards changing the landscape of medical clinics across Canada.
On September 7th, we proudly announced a signed supply agreement between wholly-owned Ascent subsidiary Agrima Botanicals and the Ontario Cannabis Retail Corporation, as well as a supply agreement with the British Columbia Liquor Distribution Branch. We are currently working towards similar agreements with other provincial liquor boards.
Earlier in September, the Agrima research team developed a proprietary methodology for producing discrete, water-soluble cannabinoids in both powder and liquid form. This new technique allows for a much faster onset time, as well as greater flexibility when creating unique formulations for the edibles and beverage markets. Water-soluble cannabinoids emulsify evenly, making it easier to standardized product mixtures, enabling us to provide a consistent consumer experience.
The timing of this new development couldn't have been better, as Agrima Labs nears its final completion phase. We are currently waiting on a level 10 vault installation and some equipment delivery, allowing the lab to become fully operational in the coming months. Once completed, our science teams will have 20,000 square feet of state of the art lab space designated for ongoing research and development, ethanol and CO2 extractions, as well as product refining, testing and packaging
Agrima_Progress
To learn more about our current facilities click here.
Employee Profile
This month, we’d like to highlight the hiring of John Sweeney as Vice President of US Operations.
Before joining Ascent, John had spent five years working in the cannabis production space, initially as a consultant, then as the VP of Operations for Privateer Holdings, parent company of Tilray - the first licensed medical cannabis producer in North America with cGMP certification. Prior to this, John spent over 15 years in senior roles within large-scale commercial manufacturing operations at leading edge biopharmaceutical companies including: Pfizer, Wyeth, and Sanofi-Aventis.
Overseeing operations at both Sweet Cannabis manufacturing facilities in Portland, Oregon and Las Vegas, Nevada; John’s stellar track record working with large-scale bio-pharmaceutical production makes him perfectly suited to help Ascent meet the requisite operational, regulatory and technical challenges of applying cGMP manufacturing principles to large-scale cannabis production.
Welcome to the team, John!
Events
Agrima_CHCE
Last month, Ascent was proud to be a Title Sponsor of the 4th annual Cannabis Hemp Conference & Expo in Vancouver. Canada’s largest and most comprehensive hemp conference featured a number of great presentations and keynote speakers, including Ascent co-founder and COO Reid Parr. Dr. Perry Kendall, a retired public health official and current Ascent board member, also took the podium, as did Dr. Zamir Punja, a SFU research scientist with whom Ascent enjoys a working partnership.
Cambridge_House
Elsewhere, Ascent was an exhibitor at the Cambridge House International Extraordinary Future event and co-founder and CEO, Philip Campbell spoke at the Okanagan Cannabis Business Symposium.
Canadian Cannabis Capital Markets Conference
Looking ahead to October, Philip Campbell will be speaking at the Canadian Cannabis Capital Markets Conference in Frankfurt, Germany on the 21st and Agrima Botanicals will be at the Montreal Cannabis Expo on the 26th and 27th.
Expo Cannabis Montréal
This is the premier cannabis event in Quebec, as well as the first post-legalization industry trade show. Locally in Richmond, British Columbia, Philip will also be presenting at the 19th Annual GCFF Vancouver Conference. Canada’s largest and fastest growing Chinese investor communities with investment opportunities in the technology, life science, mining and energy sectors.
ASNT:CNX Performance
The following graphs illustrate Ascent Industries and the Canadian Marijuana Index performance between September 5th, 2018 and October 5th, 2018. The Canadian Marijuana Index experienced a 1.5% decline while Ascent Industries was up 49% during the same period of time.
Here is a monthly summary of our stock:
ASNT
Click here to view more.
Canadian Marijuana Index Performance
Here is a monthly summary of the Canadian Marijuana Index:
MJ-INDEX
The Canadian Marijuana Index tracks the leading cannabis stocks operating in Canada. Constituents must have a business strategy focused on the marijuana or hemp industry, and are required to meet minimum trading criteria. The Index is equal-weighted and rebalanced quarterly. Click here to learn more.
As we countdown the days to October 17th, we want to thank you again for your continued support. We look forward to touching base with you again post-legalization.
Sincerely,
The Ascent Industries Team
Ascent Industries
Ascent is a trailblazing, multinational company leading a global surge in cannabis production, research, and product development. We are strategically positioned to identify and invest tactically in emerging markets.
Click here to download our Investor Presentation.
Copyright © ascentindustries.com - All rights reserved.
guay, thanks for your response, yes those are the things I am talking about.
it's not that I think there is anything underhanded going on it is just that is so convoluted and the share price has been held down so much that I don't know that there is not.
I guess I shouldn't complain in that I am still green, just wish things would start to move in the right direction and ease my mind! I really would like to know what is holding this back. GLTA :^)
AAAtrades, The gelcaps deal is certainly fine. You are right, building a manufacturing facility from scratch and figuring out how to make them on your own would not be smart. I am speaking only of those deals made with Emerald Health Sciences, which is a privately held company. I fear those deals might not be the best for Emerald Health Therapeutics, and was looking for better informed input from those who might have better knowledge than myself.
Although I am disappointed that Emerald has remained under valued and expect it will soon increase its share price :) I am also bothered by so many incestuous relationships. Who is getting the advantage with these deals? Frankly I'm not sure I trust Emerald Health Sciences, but don't really have the proper expertise to make a good judgement.
If any one has thoughts on these things I would love to hear them!!!
pretty quiet board today, I guess everyone sold and went home. :)
nice to see some green for a change,hope it hangs around for the close.
parabolic indeed, glad I was able to get those few more shares before it started to run. It will be very interesting watching this week!
PGTMF closed at high of the day (.675 US) on 5 times the volume on the OTC. LOOKING GOOD!!! GO ASCENT!! :^)